• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A vaginal ring comprises a supporting ring (1) free of active agent. A layer (2), which contains an active agent such as a steroid, is applied on its outer rim, optionally in a continuous groove provided in the supporting ring. This layer, in turn, is coated with a layer (3) devoid of active ingredient. All components preferably comprise an LTV silicone elastomer. The ratio of the thickness of the layer (2), containing an active agent, to the layer (3), free of active agent, is about 5-50 : 1. As a result, a longterm and uniform release rate is achieved for the active agent.
    公开号:SU1440326A3
    申请号:SU813347855
    申请日:1981-10-27
    公开日:1988-11-23
    发明作者:Циммерманн Ингфрид；Виндт Фред；Рек Ханс-Юрген
    申请人:Шеринг Аг (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to medicine, namely to gynecology, and relates to means of preventing pregnancy.
    The aim of the invention is to increase the time of use of the ring by ensuring the release of biologically active substances.
    The drawing shows a vaginal ring, a cross section. Yu
    Example. The vaginal ring consists of a support ring 1 containing an indentation 2 on the inner surface, in which an inner ring 3 is located, covered with a silicone membrane 4 15. For the manufacture of a support ring, 232.575 g of polydimethylsiloxane (molar mass 5854), 17.423 g of tetramethyl-tetravinyl-cyclotetrasiloxane (molar mass 20) are mixed
    5854) and 2.5 mg of platinum, as well as 193.789 g of polydimethylsiloxane and 56.211 g of polydimethylhydrosipoxane. Both mixtures are homogenized in a mixing tube, injected into a mold 15 for injection molding for 60 s at 100 ° C, and rings with a cross section in the form of a circular segment are vulcanized (deepening on the inner surface). thirty
    To make the second ring, located in the segment of the first, 49.86 g of polydimethylsiloxane with terminal vinyl groups, 0.14 G of tetramethyltetravinyl-cyclotetrasiloxane with vinyl terminal groups, 5.00 mg of platinum and 1.814 g of levonorgestrel are intensively mixed. Both mixtures are homogenized in a mixing tube, injected under pressure into a mold with a support ring inserted in it, and cured for 60 s at 100 ° C. The thickness of the layer of the second ring is 1000 microns. The manufactured ring is sprayed in the region of the second ring with a layer of silicone polymer to a thickness of 200 μm. The ratio of the thickness of the layer of the second ring and the silicone membrane is 5: 1.
    An individual ring contains 0.8% biologically active substance and has a release rate of 70.5 μg / day.
    The proposed ring allows for a long time, for several months, to use it to prevent pregnancy.
    权利要求:
    Claims (1)
    [1]
    Claim
    A vaginal silicone polymer ring, an indentation on the inner surface in which a second ring of the same polymer containing a biologically active drug is located, characterized in that, in order to increase the time of use by ensuring the release of the biologically active substance, the second ring is covered with a membrane from polymer with a ratio of their thicknesses 5: 1-50: 1.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1440326A3|1988-11-23|Vaginal ring
    AU674758B2|1997-01-09|Intravaginal delivery system
    US4292965A|1981-10-06|Intravaginal ring
    US3920805A|1975-11-18|Pharmaceutical devices and method
    US4596576A|1986-06-24|Release system for two or more active substances
    US6063395A|2000-05-16|Drug delivery device especially for the delivery of progestins and estrogens
    KR900007500B1|1990-10-11|Active agent dispenser
    JP5017109B2|2012-09-05|Sustained release composition containing a progesterone receptor modulator
    IE42345B1|1980-07-16|Vaginal ring
    JPH0649644B2|1994-06-29|Release control device
    KR920005824B1|1992-07-20|Intravaginal devices
    DE69908399T2|2004-02-05|DRUG DISPENSING SYSTEM, ESPECIALLY FOR THE ADMINISTRATION OF ANDROGENS
    AU604693B2|1991-01-03|A laminar structure for administering a chemical at a controlled release rate
    RU2001116118A|2003-03-20|DEVICE FOR DELIVERY OF MEDICINES, ESPECIALLY FOR DELIVERY OF ANDROGENS
    SU833144A3|1981-05-23|Contraceptive device
    CA2165282C|2006-10-10|Intravaginal delivery system
    JPH03209316A|1991-09-12|New multilayer percutaneous medicinal agent administration system
    Liu et al.1985|Mechanistical analysis of release kinetics for lipophilic drug from matrix-type drug delivery devices
    Nash et al.1981|Nash et al.
    SK203091A3|1994-05-11|Matrix reservoir for transdermal therapeutical system
    同族专利:
    公开号 | 公开日
    CA1165239A|1984-04-10|
    BG42182A3|1987-10-15|
    ZW26081A1|1982-05-19|
    FI78389C|1989-08-10|
    ZA817477B|1982-10-27|
    PL233606A1|1982-06-21|
    RO88674A|1986-06-30|
    DE3176606D1|1988-02-18|
    DK471481A|1982-04-29|
    JPH0324119U|1991-03-13|
    DD201645A5|1983-08-03|
    ES8505538A1|1985-06-16|
    ES527301A0|1985-06-16|
    NO813625L|1982-04-29|
    FI78389B|1989-04-28|
    IL64139A|1985-07-31|
    ES261058U|1982-05-01|
    YU252281A|1984-04-30|
    AT31875T|1988-01-15|
    FI813360L|1982-04-29|
    IE812503L|1982-04-28|
    JPH048893Y2|1992-03-05|
    IL64139D0|1982-01-31|
    NO153753B|1986-02-10|
    EG15347A|1986-03-31|
    IE54581B1|1989-12-06|
    EP0050867A1|1982-05-05|
    CS253564B2|1987-11-12|
    AU7670981A|1982-05-06|
    NO153753C|1986-05-21|
    DK151529C|1988-05-30|
    US4822616A|1989-04-18|
    DK151529B|1987-12-14|
    PT73886A|1981-11-01|
    GR75367B|1984-07-13|
    DE3040978A1|1982-05-27|
    PL127941B1|1983-12-31|
    PT73886B|1983-01-25|
    HU183646B|1984-05-28|
    EP0050867B1|1988-01-13|
    JPS5799954A|1982-06-21|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3279996A|1962-08-28|1966-10-18|Jr David M Long|Polysiloxane carrier for controlled release of drugs and other agents|
    US3545439A|1968-01-04|1970-12-08|Upjohn Co|Medicated devices and methods|
    US3845761A|1970-06-02|1974-11-05|Alza Corp|Intrauterine contraceptive anti-fertility device for the management of reproduction|
    US3854480A|1969-04-01|1974-12-17|Alza Corp|Drug-delivery system|
    CA988849A|1969-06-16|1976-05-11|Antonio Scommegna|Anti-fertility device|
    GB1264731A|1969-11-10|1972-02-23|
    US3920805A|1971-12-09|1975-11-18|Upjohn Co|Pharmaceutical devices and method|
    US3851648A|1973-10-11|1974-12-03|Mead Johnson & Co|Zero-order release device|
    FR2270899B1|1974-05-16|1979-02-16|Groves Harvey|
    DE2445971A1|1974-09-24|1976-04-08|Schering Ag|MEDICINAL INGREDIENTS CARRIERS II|
    IL48277A|1974-10-18|1978-03-10|Schering Ag|Vaginal ring|
    US4155991A|1974-10-18|1979-05-22|Schering Aktiengesellschaft|Vaginal ring|
    DE2450107A1|1974-10-18|1976-04-29|Schering Ag|VAGINAL RING|
    US4215691A|1978-10-11|1980-08-05|Alza Corporation|Vaginal contraceptive system made from block copolymer|
    US4292965A|1978-12-29|1981-10-06|The Population Council, Inc.|Intravaginal ring|DE3347125A1|1983-12-22|1985-07-11|Schering AG, 1000 Berlin und 4709 Bergkamen|MULTI-STAGE COMBINATION PREPARATION AND ITS USE FOR ORAL CONTRACTION|
    GB8430703D0|1984-12-05|1985-01-16|Lrc Products|Drug release devices|
    FR2618329B1|1987-07-22|1997-03-28|Dow Corning Sa|METHOD OF MANUFACTURING A RING CAPABLE OF ENSURING THE RELEASE OF A THERAPEUTIC AGENT, AND RING MANUFACTURED BY THIS METHOD|
    US5295984A|1989-12-07|1994-03-22|Ultrafem, Inc.|Vaginal discharge collection device and intravaginal drug delivery system|
    US6264638B1|1989-12-07|2001-07-24|Ultrafem, Inc.|Intravaginal drug delivery system and discharge collection device|
    AU1797592A|1991-04-12|1992-11-17|Upjohn Company, The|Vaginal drug delivery device|
    FI95768C|1993-06-17|1996-03-25|Leiras Oy|Intravaginal dosing system|
    GB9326255D0|1993-12-23|1994-02-23|Roussel Lab Ltd|Medical device for the prevention and treatment of cancer|
    US6544546B1|1995-07-04|2003-04-08|Akzo Nobel, N.V.|Ring-shaped devices|
    GB9522403D0|1995-11-01|1996-01-03|Hoechst Roussel Ltd|Intravaginal drug delivery device|
    US5816248A|1996-03-29|1998-10-06|Iotek, Inc.|Channeled vaginal insert and method for treating urogenital disorders|
    US6030375A|1996-03-29|2000-02-29|Iotek, Inc.|Compressible vaginal insert and method for treating urogenital disorders|
    US5988169A|1996-03-29|1999-11-23|Iotek, Inc.|Vaginal insert and method for treating urogenital disorders|
    WO1998000184A1|1996-07-03|1998-01-08|Ultrafem, Inc.|Method and system for manufacturing elastomeric articles|
    US5972372A|1996-07-31|1999-10-26|The Population Council, Inc.|Intravaginal rings with insertable drug-containing core|
    TW358031B|1997-04-11|1999-05-11|Akze Nobel N V|Drug delivery system for 2 or more active substances|
    US6039968A|1997-06-24|2000-03-21|Hoechst Marion Roussel|Intravaginal drug delivery device|
    JP2002513690A|1998-05-01|2002-05-14|エフイ−アイエンタープライジズ，リミティド|Injection molding manufacturing method for controlled release device|
    AU2001286726B2|2000-08-24|2007-03-22|Sidney Lerner|Non-hormonal vaginal contraceptive|
    AT314822T|2000-10-10|2006-02-15|Microchips Inc|MICROCHIP RESERVOIR DEVICES WITH WIRELESS TRANSMISSION OF ENERGY AND DATA|
    JP2005503389A|2001-08-31|2005-02-03|シエーリングオサケユイチア|Drug delivery system|
    US7497855B2|2002-09-04|2009-03-03|Microchips, Inc.|Method and device for the controlled delivery of parathyroid hormone|
    US7357046B2|2002-12-16|2008-04-15|N. V. Organon|Method for dissolution testing of a pharmaceutical delivery device|
    WO2004096151A2|2003-04-29|2004-11-11|The General Hospital Corporation|Methods and devices for the sustained release of multiple drugs|
    TWI336627B|2003-05-23|2011-02-01|Organon Nv|Drug delivery system,and use and manufacturing method thereof|
    DE602005015090D1|2004-03-24|2009-08-06|Organon Nv|DRUG DISPENSING SYSTEM BASED ON POLYETHYLENE VINYL ACETATE COPOLYMERS|
    US20080076975A1|2005-01-25|2008-03-27|Microchips, Inc.|Method and implantable device with reservoir array for pre-clinical in vivo testing|
    US7488316B2|2005-01-25|2009-02-10|Microchips, Inc.|Control of drug release by transient modification of local microenvironments|
    CN1899643B|2005-07-20|2010-12-29|上海市计划生育科学研究所|Pessary or intrauterine medicine release device containing antiestrogenic and anti-pregnant hormone composite preparation and its use|
    US8399012B2|2006-04-17|2013-03-19|Kimberly-Clark Worldwide, Inc.|Degradable therapeutic delivery device|
    AR066166A1|2007-09-21|2009-07-29|Organon Nv|DRUG SUPPLY SYSTEM|
    TW200927141A|2007-11-22|2009-07-01|Bayer Schering Pharma Oy|Vaginal delivery system|
    SG187529A1|2008-02-04|2013-02-28|Teva Womens Health Inc|Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof|
    US20100040671A1|2008-08-12|2010-02-18|Ahmed Salah U|Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof|
    US8420153B2|2008-09-19|2013-04-16|Mentor Worldwide Llc|Coating with antimicrobial agents|
    US8419793B2|2008-09-19|2013-04-16|Mentor Worldwide Llc|Coating with antimicrobial agents|
    CN102596097B|2009-06-03|2015-05-20|弗赛特实验室有限责任公司|Anterior segment drug delivery|
    IN2012DN00711A|2009-07-21|2015-06-19|Population Council Inc|
    WO2011140375A1|2010-05-05|2011-11-10|Diliberti Charles E|Methods of reducing symptoms in subjects using single dosage forms with tapering release rates|
    US8580294B2|2010-10-19|2013-11-12|International Partnership For Microbicides|Platinum-catalyzed intravaginal rings|
    WO2012121811A1|2011-03-04|2012-09-13|Arstat, Inc.|Treatment of excessive menstrual blood loss by intravaginal administration of low doses of antifibronlytic or hemostatic agent|
    WO2012121767A1|2011-03-09|2012-09-13|Arstat, Inc.|Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator , anti-progestin, or anti-progestational agent|
    DE202011110356U1|2011-03-10|2014-01-15|Arstat, Inc.|Treatment of endometriosis by intravaginal administration of a low dose of a selective progesterone receptor modulator, an antigestagens or an antigestagen agent|
    WO2012138542A1|2011-04-07|2012-10-11|Arstat, Inc.|Treatment of menstrual pain and excessive menstrual blood loss by intravaginal administration of a low dose of antifibrinolytic or hemostatic agent in combination with non- steroidal anti-inflammatory drug|
    AU2012268068B2|2011-06-06|2016-10-13|Auritec Pharmaceuticals|Drug delivery device employing wicking release window|
    RU2618194C2|2011-09-14|2017-05-02|Форсайт Вижн5, Инк.|Eye inserter and methods|
    US20130338122A1|2012-06-18|2013-12-19|Therapeuticsmd, Inc.|Transdermal hormone replacement therapies|
    US9301920B2|2012-06-18|2016-04-05|Therapeuticsmd, Inc.|Natural combination hormone replacement formulations and therapies|
    MX365818B|2011-11-23|2019-05-30|Therapeuticsmd Inc|Natural combination hormone replacement formulations and therapies.|
    US10537581B2|2012-12-21|2020-01-21|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|
    US10806740B2|2012-06-18|2020-10-20|Therapeuticsmd, Inc.|Natural combination hormone replacement formulations and therapies|
    US20150196640A1|2012-06-18|2015-07-16|Therapeuticsmd, Inc.|Progesterone formulations having a desirable pk profile|
    US11246875B2|2012-12-21|2022-02-15|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|
    US10471072B2|2012-12-21|2019-11-12|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|
    US11266661B2|2012-12-21|2022-03-08|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|
    US10568891B2|2012-12-21|2020-02-25|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|
    US10806697B2|2012-12-21|2020-10-20|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|
    RU2652063C2|2012-10-26|2018-04-24|Форсайт Вижн5, Инк.|Ophthalmic system for sustained release of drug to eye|
    US9180091B2|2012-12-21|2015-11-10|Therapeuticsmd, Inc.|Soluble estradiol capsule for vaginal insertion|
    WO2015055789A1|2013-10-17|2015-04-23|Bayer Pharma Aktiengesellschaft|INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION|
    US10137031B2|2013-11-14|2018-11-27|International Partnership For Microbicides, Inc.|Combination therapy intravaginal rings|
    US10596103B2|2013-12-11|2020-03-24|Merek Sharp & Dohme B.V.|Drug delivery system for delivery of anti-virals|
    US10413504B2|2013-12-11|2019-09-17|Merck Sharp & Dohme Corp.|Intravaginal ring drug delivery system|
    DE102014004388A1|2014-03-26|2015-10-01|Angela Kayser|Method and system for intravaginal administration of progesterone|
    JP2017516768A|2014-05-22|2017-06-22|セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ．|Natural combination hormone replacement therapy and therapy|
    US20160296532A1|2015-04-13|2016-10-13|Forsight Vision5, Inc.|Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent|
    EP3294300A1|2015-05-13|2018-03-21|Bayer Oy|A long acting drug delivery device and its use in contraception|
    US10328087B2|2015-07-23|2019-06-25|Therapeuticsmd, Inc.|Formulations for solubilizing hormones|
    CA3018148A1|2016-03-23|2017-09-28|The University Of North Carolina At Chapel Hill|Geometrically complex intravaginal rings, systems and methods of making the same|
    US10286077B2|2016-04-01|2019-05-14|Therapeuticsmd, Inc.|Steroid hormone compositions in medium chain oils|
    EP3435977A4|2016-04-01|2019-10-16|Therapeuticsmd, Inc.|Steroid hormone pharmaceutical composition|
    WO2018202574A1|2017-05-04|2018-11-08|Bayer Oy|Intravaginal drug delivery system, method for manufacturing such system and its use in gynecological therapies and contraception|
    DE102017113166A1|2017-06-14|2018-12-20|Amw Gmbh|Depot form for dispensing an estrogen active ingredient|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE19803040978|DE3040978A1|1980-10-28|1980-10-28|VAGINAL RING|
    [返回顶部]